Results of PureTech's Annual General Meeting
14 June 2023 - 2:40AM
Business Wire
The Annual General Meeting of PureTech Health plc (Nasdaq: PRTC,
LSE: PRTC) (“PureTech Health” or the “Company”) was held at 11 a.m.
EDT/4 p.m. BST on Tuesday, June 13, 2023.
All of the resolutions proposed at the Annual General Meeting
were duly passed by the shareholders on a poll.
The results of the poll, incorporating the proxy votes lodged in
advance of the meeting, are set out below. All resolutions were
passed by greater than 93% of the shares voted at the meeting.
Resolutions
For
%
Against
%
Withheld
Total votes cast
001. To approve the Company’s Annual
Report and Accounts for year ended 31 December 2022
218,239,144
100.00%
0
0.00%
1,856
218,239,144
002. To approve the Directors’
Remuneration Report
208,436,087
95.51%
9,804,137
4.49%
776
218,240,224
003. To elect Ms. Sharon Barber-Lui as a
director
217,708,896
99.76%
530,758
0.24%
1,346
218,239,654
004. To elect Dr. Raju Kucherlapati as a
director
217,673,486
99.74%
564,168
0.26%
3,346
218,237,654
005. To elect Dr. John LaMattina as a
director
208,905,865
95.72%
9,331,788
4.28%
3,347
218,237,653
006. To elect Ms. Kiran Mazumdar-Shaw as a
director
204,963,784
93.92%
13,275,369
6.08%
1,847
218,239,153
007. To elect Dr. Robert Langer as a
director
213,495,366
97.83%
4,743,812
2.17%
1,822
218,239,178
008. To elect Ms. Daphne Zohar as a
director
218,236,986
100.00%
2,693
0.00%
1,321
218,239,679
009. To elect Dr. Bharatt Chowrira as a
director
217,679,376
99.99%
30,161
0.01%
531,463
217,709,537
010. To appoint PricewaterhouseCoopers LLP
as the auditors of the Company
217,704,419
99.75%
535,776
0.25%
805
218,240,195
011. To authorize the Audit Committee to
determine the Auditors' remuneration
218,232,344
100.00%
6,151
0.00%
2,505
218,238,495
012. To authorize the allotment of
shares
218,208,524
99.99%
31,471
0.01%
1,005
218,239,995
013. To approve the Company’s new
Performance Share Plan
211,285,130
96.81%
6,952,233
3.19%
3,637
218,237,363
014. To disapply pre-emption rights
217,137,254
99.50%
1,101,010
0.50%
2,736
218,238,264
015. To further disapply pre-emption
rights as if section 561 of the Companies Act 2006 did not apply to
any allotment of equity securities for cash or sale of treasury
shares for cash
214,933,920
98.49%
3,304,344
1.51%
2,736
218,238,264
016. To authorize market purchase of own
shares
217,711,818
99.76%
528,167
0.24%
1,015
218,239,985
017. To authorize general meetings to be
called on not less than 14 clear days’ notice
217,917,408
99.85%
322,238
0.15%
1,354
218,239,646
Notes:
- A vote “Withheld” is not a vote in law and is not counted in
the calculation of the votes “For” or “Against” a resolution.
- As at June 9, 2023, the record date for the Annual General
Meeting, the number of issued shares in the Company entitling the
holders to attend and vote for or against all the resolutions at
the AGM was 277,430,684 ordinary shares. This does not include
12,037,475 shares held in treasury by the Company. In accordance
with the Company’s Articles of Association, on a poll every member
present in person or by proxy has one vote for every share
held.
- The full text of the resolutions may be found in the Notice of
the Annual General Meeting, copies of which are available on both
the Company’s website
https://investors.puretechhealth.com/financials-filings/reports and
on the National Storage Mechanism.
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated
to giving life to new classes of medicine to change the lives of
patients with devastating diseases. The Company has created a broad
and deep pipeline through its experienced research and development
team and its extensive network of scientists, clinicians and
industry leaders that is being advanced both internally and through
its Founded Entities. PureTech's R&D engine has resulted in the
development of 27 therapeutics and therapeutic candidates,
including two (Plenity® and EndeavorRx®) that have received both US
FDA clearance and European marketing authorization and a third
(KarXT) that is expected to be filed soon for FDA approval. A
number of these programs are being advanced by PureTech or its
Founded Entities in various indications and stages of clinical
development, including registration enabling studies. All of the
underlying programs and platforms that resulted in this pipeline of
therapeutic candidates were initially identified or discovered and
then advanced by the PureTech team through key validation
points.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are or may be
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements contained
in this press release that do not relate to matters of historical
fact should be considered forward-looking statements, including
without limitation those related to our future prospects,
developments and strategies. The forward-looking statements are
based on current expectations and are subject to known and unknown
risks, uncertainties and other important factors that could cause
actual results, performance and achievements to differ materially
from current expectations, including, but not limited to, those
risks, uncertainties and other important factors described under
the caption "Risk Factors" in our Annual Report on Form 20-F for
the year ended December 31, 2022 filed with the SEC and in our
other regulatory filings. These forward-looking statements are
based on assumptions regarding the present and future business
strategies of the Company and the environment in which it will
operate in the future. Each forward-looking statement speaks only
as at the date of this press release. Except as required by law and
regulatory requirements, we disclaim any obligation to update or
revise these forward-looking statements, whether as a result of new
information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230613241795/en/
PureTech Investor Relations
IR@puretechhealth.com
PureTech Health (NASDAQ:PRTC)
Historical Stock Chart
From Aug 2024 to Sep 2024
PureTech Health (NASDAQ:PRTC)
Historical Stock Chart
From Sep 2023 to Sep 2024